Puma Biotechnology (PBYI) Competitors

$7.08 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$7.08 0.00 (-0.07%)

As of 05/22/2026 06:37 PM Eastern

PBYI vs. ADMA, CTMX, TRDA, URGN, and CMPS

Should you buy Puma Biotechnology stock or one of its competitors? MarketBeat compares Puma Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Urogen Pharma (URGN), and Compass Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry.

How does Puma Biotechnology compare to ADMA Biologics?

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.75
ADMA Biologics	$510.17M	3.74	$146.93M	$0.68	12.12

Puma Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics has a consensus price target of $19.00, indicating a potential upside of 130.58%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, ADMA Biologics had 10 more articles in the media than Puma Biotechnology. MarketBeat recorded 10 mentions for ADMA Biologics and 0 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.00 beat ADMA Biologics' score of -0.13 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Neutral
ADMA Biologics	Neutral

ADMA Biologics has a net margin of 32.43% compared to Puma Biotechnology's net margin of 10.69%. ADMA Biologics' return on equity of 39.98% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
ADMA Biologics	32.43%	39.98%	28.08%

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, CytomX Therapeutics had 4 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 0 mentions for Puma Biotechnology. CytomX Therapeutics' average media sentiment score of 0.65 beat Puma Biotechnology's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CytomX Therapeutics	Positive
Puma Biotechnology	Neutral

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	8.40	-$17.37M	-$0.41	N/A
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.75

Puma Biotechnology has a net margin of 10.69% compared to CytomX Therapeutics' net margin of -166.40%. Puma Biotechnology's return on equity of 20.30% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Puma Biotechnology	10.69%	20.30%	12.05%

CytomX Therapeutics presently has a consensus target price of $12.10, indicating a potential upside of 221.81%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

CytomX Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CytomX Therapeutics beats Puma Biotechnology on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.75
Entrada Therapeutics	$25.42M	10.02	-$143.75M	-$3.99	N/A

Entrada Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 178.20%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 5 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Entrada Therapeutics and 0 mentions for Puma Biotechnology. Entrada Therapeutics' average media sentiment score of 0.43 beat Puma Biotechnology's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Puma Biotechnology	Neutral
Entrada Therapeutics	Neutral

Puma Biotechnology has a net margin of 10.69% compared to Entrada Therapeutics' net margin of -2,895.05%. Puma Biotechnology's return on equity of 20.30% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Summary

Puma Biotechnology beats Entrada Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Urogen Pharma has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Puma Biotechnology has a net margin of 10.69% compared to Urogen Pharma's net margin of -94.83%. Puma Biotechnology's return on equity of 20.30% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Puma Biotechnology	10.69%	20.30%	12.05%

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.75

In the previous week, Urogen Pharma had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 1 mentions for Urogen Pharma and 0 mentions for Puma Biotechnology. Urogen Pharma's average media sentiment score of 0.26 beat Puma Biotechnology's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Urogen Pharma	Neutral
Puma Biotechnology	Neutral

Urogen Pharma currently has a consensus price target of $36.67, suggesting a potential upside of 26.92%. Given Urogen Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Urogen Pharma is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Urogen Pharma beats Puma Biotechnology on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Compass Pathways?

Puma Biotechnology (NASDAQ:PBYI) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Puma Biotechnology has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.75
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Compass Pathways has a consensus target price of $20.58, suggesting a potential upside of 74.29%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Compass Pathways had 13 more articles in the media than Puma Biotechnology. MarketBeat recorded 13 mentions for Compass Pathways and 0 mentions for Puma Biotechnology. Compass Pathways' average media sentiment score of 0.60 beat Puma Biotechnology's score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Overall Sentiment
Puma Biotechnology	Neutral
Compass Pathways	Positive

Puma Biotechnology has a net margin of 10.69% compared to Compass Pathways' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Compass Pathways	N/A	-31.07%	-11.40%

Summary

Puma Biotechnology beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$360.36M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	14.75	18.74	21.22	25.65
Price / Sales	1.58	323.98	553.92	86.28
Price / Cash	8.49	125.17	43.49	56.67
Price / Book	2.81	7.09	10.37	7.14
Net Income	$31.11M	$24.45M	$3.57B	$335.98M
7 Day Performance	3.96%	5.45%	6.01%	3.56%
1 Month Performance	-6.10%	2.43%	3.52%	2.54%
1 Year Performance	119.20%	62.98%	34.13%	35.05%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBYI Puma Biotechnology	1.2957 of 5 stars	$7.08 flat	N/A	+119.2%	$360.36M	$228.40M	14.75	200
ADMA ADMA Biologics	4.5436 of 5 stars	$8.38 +1.3%	$19.00 +126.7%	-59.6%	$1.92B	$510.17M	12.32	530	Gap Up
CTMX CytomX Therapeutics	3.1359 of 5 stars	$3.50 -3.0%	$12.78 +265.1%	+68.6%	$614.37M	$76.20M	N/A	170
TRDA Entrada Therapeutics	3.9242 of 5 stars	$5.89 -7.7%	$18.25 +209.8%	-12.5%	$247.68M	$5.74M	N/A	110
URGN Urogen Pharma	3.3458 of 5 stars	$28.58 -0.7%	$36.67 +28.3%	+589.5%	$1.40B	$109.79M	N/A	200	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, URGN, and CMPS

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to Urogen Pharma?

Summary

How does Puma Biotechnology compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, URGN, and CMPS

How does Puma Biotechnology compare to ADMA Biologics?

Which has better valuation and earnings, PBYI or ADMA?

Which has more volatility and risk, PBYI or ADMA?

Do insiders and institutionals hold more shares of PBYI or ADMA?

Do analysts rate PBYI or ADMA?

Does the media refer more to PBYI or ADMA?

Is PBYI or ADMA more profitable?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Does the media prefer CTMX or PBYI?

Which has preferable valuation and earnings, CTMX or PBYI?

Is CTMX or PBYI more profitable?

Do analysts prefer CTMX or PBYI?

Which has more volatility and risk, CTMX or PBYI?

Do institutionals & insiders believe in CTMX or PBYI?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Do institutionals and insiders have more ownership in PBYI or TRDA?

Which has higher valuation & earnings, PBYI or TRDA?

Do analysts prefer PBYI or TRDA?

Which has more risk & volatility, PBYI or TRDA?

Does the media favor PBYI or TRDA?

Is PBYI or TRDA more profitable?

Summary

How does Puma Biotechnology compare to Urogen Pharma?

Which has more volatility & risk, URGN or PBYI?

Is URGN or PBYI more profitable?

Do insiders and institutionals have more ownership in URGN or PBYI?

Which has better earnings and valuation, URGN or PBYI?

Does the media prefer URGN or PBYI?

Do analysts prefer URGN or PBYI?

Summary

How does Puma Biotechnology compare to Compass Pathways?

Which has preferable earnings and valuation, PBYI or CMPS?

Do analysts recommend PBYI or CMPS?

Which has more risk & volatility, PBYI or CMPS?

Do institutionals & insiders hold more shares of PBYI or CMPS?

Does the media favor PBYI or CMPS?

Is PBYI or CMPS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools